Evidence map›Paper›PMID 41808316›Full record

ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2026

Completion of the Icatibant Outcome Survey and What We Learned.

Laurence Bouillet, Werner Aberer, Teresa Caballero, Anete S Grumach, Hilary J Longhurst, Alissa Dangel, Natalie Khutoryansky, Irmgard Andresen, Andrea Zanichelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Completion of the Icatibant Outcome Survey and What We Learned.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laurence BouilletNational Reference Centre for Angioedema, Internal Medicine Department, Grenoble University Hospital, Grenoble, France.ORCID https://orcid.org/0000-0001-8245-4767
Werner AbererDepartment of Dermatology and Venereology, Medical University of Graz, Austria.
Teresa CaballeroNational Reference Center (CSUR) for Hereditary Angioedema, Department of Allergy, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPAZ), Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, Spain.
Anete S GrumachClinical Immunology, Faculdade de Medicina, Centro Universitario Faculdade de Medicina ABC (CEUFMABC), Santo Andre, Brazil.ORCID https://orcid.org/0000-0002-9803-0309
Hilary J LonghurstDepartment of Medicine, University of Auckland and Auckland City Hospital, Auckland, New Zealand.ORCID https://orcid.org/0000-0003-2891-566X
Alissa DangelTakeda Pharmaceuticals USA, Inc., Cambridge, Massachusetts, USA.
Natalie KhutoryanskyTakeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Irmgard AndresenTakeda Pharmaceuticals International AG, Zurich, Switzerland.
Andrea ZanichelliOperative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato, Milan, Italy.

Funding

Takeda Development Center Americas, Inc., Lexington, MA, USA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical outcomeshereditary angioedemaicatibantlong‐term safety

Identifiers

PMID41808316
PMCPMC13327162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.